Everything you need to win Aditum Bio and Leads Biolabs — in one platform.
Who to reach, what to say, and why now on Aditum Bio and Leads Biolabs — plus every funding round, exec hire, and M&A move that follows, each with the verified contact and the outreach written for you.
Get the full Deep Dive on Aditum Bio and Leads Biolabs — free.
One free Deep Dive, emailed to you. No spam; unsubscribe anytime.
The decision-maker’s email and mobile — dial in-browser.
Aditum Bio and Leads Biolabs Form Oblenio Bio to Develop Tri-Specific T-Cell Engager for Autoimmune Disorders
Nov 07, 2024•over 1 year ago
Contract Type
partnership
Biotechnology
Description
Aditum Bio and Leads Biolabs have formed a partnership to create Oblenio Bio, with an exclusive option and license agreement to develop LBL-051, a first-in-class CD19xBCMAxCD3 tri-specific T-cell engager antibody for autoimmune diseases. The collaboration aims to rapidly bring LBL-051 into clinical studies to address unmet needs for increased efficacy and durability in difficult-to-treat autoimmune diseases.
Company Information
Company
Aditum Bio and Leads Biolabs
About
Aditum Bio and Leads Biolabs are biotechnology companies involved in the formation of Oblenio Bio to develop a tri-specific T-cell engager for autoimmune disorders.
Predictive Intelligence
Strategic
ML-powered predictions for Aditum Bio and Leads Biolabs's next move
